Skip to main content
. 2017 Aug 24;8(61):103014–103031. doi: 10.18632/oncotarget.20488

Figure 1. Dasatinib resistant cells exhibit differential sensitivity to the Src inhibitors, saracatinib and bosutinib.

Figure 1

(A) Dasatinib IC50 values of control and dasatinib-resistant (DasRes) cell lines that were calculated based on a growth curve with concentrations ranging from 0 - 10μM. (B-C) Sulfurhodamine B (SRB) growth assays were performed on the DasRes cell lines to determine sensitivity to saracatinib (B) and bosutinib (C). Three independent biological replicates were performed, and the standard error mean is displayed in the quantification graphs. (D-E) BRAF-mutant (D) and RAS-mutant (E) control and DasRes whole cell lysate was harvested after 24 hour treatments of DMSO, dasatinib, bosutinib, or saracatinib. Control cell lines were treated with 100nM dasatinib, and DasRes cell lines were treated with 2μM dasatinib. FAK/Src signaling was used to determine whether each inhibitor had similar efficacy at inhibiting Src activity. Three independent biological replicates were performed, and representative blots for signaling proteins and loading controls are shown. The pY416 Src blot was stripped and reprobed for total Src.